SciSparc

SPRC

Market cap $3.85M

TEL AVIV, Israel, Aug. 05, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced the initiation of NeuroThera's Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera's proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome (“TS”) in adults.

Toronto, Ontario – TheNewswire - A ugust 5 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at the Yale Child Study Center, Yale School of Medicine, New Haven, Connecticut, USA. The study, led by Dr. Michael H. Bloch, will evaluate SCI-110, NeuroThera's proprietary cannabinoid-based drug candidate for the treatment of Tourette Syndrome (“TS”) in adults.   The trial is now progressing at the Yale Child Study Center, one of the study's key clinical sites. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in a single, innovative dosage form designed to reduce tics and associated comorbid symptoms in adults with TS while aiming to minimize side effects.

SciSparc Ltd. (NASDAQ:SPRC) shares are down more than 20% on Friday.

TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced another technological milestone achieved by NeuroThera's quantum sampling workflow platform for clinical trials data analytics (the “Platform”).

TEL AVIV, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, has successfully completed internal validation of a proprietary quantum sampling workflow developed platform for clinical trials data analysis (the “Platform”).

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence (“AI”) market.

TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at  Hannover Medical School, Hanover, Germany (“MHH”), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.

Toronto, Ontario – TheNewswire - July 15, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced the initiation of its Phase IIb clinical trial site at  Hannover Medical School, Hanover (“MHH”), Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.   The trial, which previously received regulatory clearance from Germany's Federal Institute for Drugs and Medical Devices and MHH's ethics committee , is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects.

Toronto, ON – July 2, 2026 - TheNewswire – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, further to its press release dated June 30, 2026, it has increased the size of its previously announced non-brokered private placement (the " Offering ") and extended the expiry term of the Unit Warrants (as defined below). The Company now intends to issue up to 45,000,000 units (each, an “ Offered Unit ”) at a price of C$0.12 per Offered Unit for gross proceeds of up to approximately C$5,400,000 under the Offering.     Each Offered Unit will be comprised of one (1) common share in the capital of the Company (each, a “ Unit Share ”) and one (1) transferable common share purchase warrant (each, a “ Unit Warrant ”) entitling the holder thereof to acquire one common share in the capital of the Company (each, a “ Unit Warrant Share ”) at a USD exercise price equivalent to C$0.16 per Unit Warrant Share (to be calculated on the date of closing of the Offering) for a period of 36 months from the date of issuance thereof, an increase to the previously announced 24 month expiry period for the Unit Warrants.  The Unit Warrants will also have an acceleration provision whereby upon the securities of NeuroThera being approved for trading on the Nasdaq Stock Market, NeuroThera will accelerate the expiry date of 50% of the unexercised Unit Warrants.

Toronto, ON – TheNewswire - June 30, 2026 – NeuroThera Labs Inc. (the “ Company ” or “ NeuroThera ”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it will be proceeding with a non-brokered private placement of up to 37,050,000 units (the " Offered Units ") at a price of C$0.135 per Offered Unit for gross proceeds of up to approximately C$5,000,000 (the " Offering ").   Each Offered Unit will be comprised of one (1) common share in the capital of the Company (each, a “ Unit Share ”) and one (1) transferable common share purchase warrant (each, a “ Unit Warrant ”) entitling the holder thereof to acquire one common share in the capital of the Company (each, a “ Unit Warrant Share ”) at a price of C$0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof.  The Unit Warrants will also have an acceleration provision whereby upon the approval of securities of NeuroThera for trading on the Nasdaq Stock Market, NeuroThera will accelerate the expiry date of 50% of the unexercised Unit Warrants.